Company Filing History:
Years Active: 2020
Title: Johnny Vercouillie: Innovator in Cancer Imaging
Introduction
Johnny Vercouillie is a notable inventor based in Tours, France. He has made significant contributions to the field of medical imaging, particularly in the diagnosis and treatment of cancer. His innovative work focuses on the development of radiolabeled compounds that enhance the imaging of epidermal growth factor receptors (EGFR).
Latest Patents
Johnny Vercouillie holds a patent for a radiolabeled macrocyclic EGFR inhibitor. This invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging EGFR. The patent outlines their use in in vivo diagnosis, preclinical and clinical tumor imaging, and patient stratification based on the mutational status of EGFR. It also describes methods for preparing the radiotracers and is relevant to various cancers influenced by deregulated EGFR, including non-small cell lung cancer, pancreatic cancer, and breast cancer.
Career Highlights
Johnny Vercouillie is associated with Oncodesign SA, a company dedicated to advancing cancer treatment through innovative technologies. His work has positioned him as a key figure in the development of diagnostic tools that can significantly impact patient care.
Collaborations
Some of his notable coworkers include Jan Marie Cyriel Jozef Hoflack and Cyril Berthet. Their collaborative efforts contribute to the advancement of cancer research and imaging technologies.
Conclusion
Johnny Vercouillie is a pioneering inventor whose work in radiolabeled compounds is making strides in cancer diagnosis and treatment. His contributions are vital for improving patient outcomes in oncology.